United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...
Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval in the European Union...
Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing
US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...
Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody
China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...
Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline
China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...
Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development
China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...
FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial
France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...
Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder
US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...
CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors
Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...
Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits
China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...
Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...
Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA
Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...
Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...
Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism
President Donald Trump has signed an executive order indicating the withdrawal of the United States...
Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun
The Beijing Municipal Health Commission has approved Douyin, the Chinese short-form video hosting service owned...
NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit
China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...
Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...
MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...
Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...